細胞療法製造市場－全球產業規模、佔有率、趨勢、競爭格局、機會及預測（依治療方法、細胞來源、營運規模、供應來源、應用、最終用戶、地區和競爭格局分類），2021-2031年

全球細胞治療製造市場預計將從2025年的57.1億美元成長到2031年的114.2億美元，複合年成長率（CAGR）為12.25%。該行業涵蓋了分離、基因改造、擴增和冷凍保存用於自體或異體移植療法的活性細胞所需的專業生物製程活動。市場成長的主要驅動力是全球腫瘤和罕見遺傳疾病發生率的不斷上升，加劇了對治療性介入的迫切需求。同時，法規環境的日趨成熟也促進了核准的加速以及對專用生產基礎設施的投資。

根據美國基因與細胞治療學會 (ASGCT) 和 Citeline 的數據，預計到 2025 年，全球基因和細胞治療藥物開發平臺將保持強勁勢頭，屆時將有超過 3200 項臨床試驗正在進行中。雖然如此龐大的臨床候選藥物數量推動了對大規模生產能力的需求，但該產業在成本效益方面也面臨嚴峻挑戰。具體而言，如何維持從病人到病人的供應鏈完整性，以及擴大生產規模的難度，都對降低這些先進醫療療法的高昂銷貨成本構成了重大障礙。

市場促進因素

支持性的法規環境和加快核准流程正在從根本上改變製造業，加速複雜治療方法的商業化進程。隨著監管機構最佳化審查流程，該行業正迅速從臨床規模的生產轉向大規模商業化生產，市場參與企業數量的增加便是這一轉變的有力佐證。根據再生醫學聯盟（Alliance for Regenerative Medicine）統計，截至2025年1月，該產業在2024年已獲得9種新產品核可。如此激增的核准需要一條具有韌性的供應鏈和可擴展的基礎設施，能夠在加快核准速度的同時滿足嚴格的品質標準。

因此，為了避免自建設施帶來的巨額資本成本和技術負擔，製藥公司越來越依賴合約研發生產力機構（CDMO）。為了滿足這種外包需求，CDMO正在積極擴張。例如，三星生物製劑於2025年12月宣布計畫投資48億美元建造一座新的生物園區，該園區將配備新一代細胞和基因治療技術。牛津生物醫藥公司也反映了這一趨勢，該公司報告稱，截至2025年9月，其上半年已獲得價值1.49億英鎊的新客戶訂單，凸顯了專業合作夥伴的重要性。

市場挑戰

全球細胞療法生產市場成長的主要障礙是成本效益嚴重不足以及維持供應鏈完整性的困難。由於勞力密集且擴充性的工作流程，導致銷貨成本，使得治療費用高到醫療報銷體系無法承受的地步。這種經濟壓力限制了可接受治療的患者群體，並阻礙了針對更廣泛疾病的治療方法的商業化。因此，該市場實際上僅限於支付方能夠承擔高成本的特定適應症。

根據再生醫學聯盟預測，到2025年，全球再生醫學領域75%的收入將來自不到10種上市產品。這種收入集中度凸顯了強大的臨床研發管線與實際商業性可行性之間的脫節，並顯示將臨床成功轉化為盈利且可擴展的生產營運存在重大瓶頸。因此，擴大生產規模所帶來的財務風險對許多開發商而言仍然難以承受，由於無法支持多樣化的治療方法，市場擴張受到阻礙。

市場趨勢

採用自動化和封閉式系統處理平台正成為解決產業勞動密集瓶頸和一致性問題的關鍵方案。製造商正積極利用整合式智慧工廠模組，以精準的機器人操作取代人工，確保批次均一性並降低污染風險。這種技術革新使得產能無需成比例增加設施規模或人員即可顯著提升，例如，Cellares公司於2024年9月在新澤西州運作的工廠，每年可生產多達4萬劑標準CAR-T細胞療法。

同時，分散式和照護現場生產模式的興起正在革新傳統的集中式供應鏈，將生產能力置於臨床環境之內或附近。這種策略透過在現場處理患者樣本，顯著縮短了從靜脈到靜脈的運輸時間，並減少了物流障礙，有效地將醫院轉變為生物製造中心。德克薩斯大學MD安德森癌症中心於2024年11月推出了一個新的研究機構，旨在加速細胞治療方法的內部發現和生產，該機構獲得了超過8000萬美元的資助，這正是領先的學術和臨床機構如何資助這一變革的一個例證。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球細胞療法製造市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療方法（T細胞療法、樹突細胞療法、癌細胞療法、幹細胞療法）
  • 依細胞來源（自體細胞與異體細胞）
  • 依企業規模（臨床前、臨床、商業）
  • 依供應來源（內部生產與契約製造）分類
  • 依應用領域（腫瘤科、心血管疾病科、整形外科疾病科等）
  • 依最終用戶（製藥/生技公司、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞療法製造市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲細胞療法製造市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太細胞療法製造市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細胞療法製造市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲細胞療法製造市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球細胞療法製造市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Lonza
• Thermo Fisher
• Catalent
• WuXi AppTec
• Novartis
• Gilead
• Bristol Myers Squibb
• Merck KGaA
• Cytiva
• Charles River

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cell Therapy Manufacturing Market is projected to expand from USD 5.71 Billion in 2025 to USD 11.42 Billion by 2031, reflecting a compound annual growth rate of 12.25%. This sector comprises specialized bioprocessing activities essential for isolating, genetically modifying, expanding, and cryopreserving viable cells used in autologous or allogeneic therapies. Market growth is primarily propelled by the increasing global prevalence of oncological and rare genetic disorders, creating an urgent need for curative interventions, while maturing regulatory environments encourage expedited approvals and investment in dedicated production infrastructure.

Data from the American Society of Gene & Cell Therapy and Citeline indicates that the global pipeline remained strong in 2025, with over 3,200 active trials. While this high volume of clinical candidates drives the need for extensive manufacturing capacity, the industry faces substantial hurdles related to cost-efficiency. Specifically, the complexity involved in preserving supply chain integrity from patient to patient, combined with the difficulties of scaling production, creates a significant barrier to lowering the high cost of goods sold for these advanced medical treatments.

Market Driver

Supportive regulatory environments and accelerated approval pathways are fundamentally transforming the manufacturing sector by speeding up the commercial launch of complex therapies. As health authorities optimize review procedures, the industry is rapidly moving from clinical-scale operations to high-volume commercial production, a shift underscored by a growing number of market participants. According to the Alliance for Regenerative Medicine, the sector achieved nine new product approvals in 2024 as of January 2025; this surge in authorizations demands resilient supply chains and scalable infrastructure capable of meeting strict quality standards under expedited timelines.

Consequently, there is an increasing dependence on Contract Development and Manufacturing Organizations as developers aim to avoid the heavy capital costs and technical burdens of building internal facilities. CDMOs are aggressively expanding to meet this outsourcing demand, as seen in Samsung Biologics' December 2025 announcement of a $4.8 billion investment for a new bio-campus featuring next-generation cell and gene therapy capabilities. This trend is further evidenced by Oxford Biomedica, which reported signing £149 million in new client orders during the first half of the year in September 2025, underscoring the critical role of specialized partners.

Market Challenge

The primary obstacles restricting the Global Cell Therapy Manufacturing Market's growth are the significant lack of cost-efficiency and the difficulties associated with maintaining supply chain integrity. High costs of goods sold, resulting from labor-intensive and unscalable workflows, inflate therapy prices to levels that challenge healthcare reimbursement systems. This economic pressure restricts the accessible patient demographic and deters the commercialization of treatments for broader conditions, effectively confining the market to niche indications where high costs are absorbed by payers.

According to the Alliance for Regenerative Medicine, 75% of the sector's global revenue in 2025 came from fewer than ten commercial products. This intense revenue concentration reveals a disconnect between a strong clinical pipeline and actual commercial viability, indicating a major bottleneck in converting clinical successes into profitable, scalable manufacturing operations. As a result, market expansion is hindered by the inability to support a diverse array of therapies, as the financial risks involved in scaling production remain prohibitively high for many developers.

Market Trends

The implementation of automated and closed-system processing platforms is becoming a vital solution to the industry's labor-intensive bottlenecks and consistency issues. Manufacturers are increasingly utilizing integrated smart factory modules that substitute manual handling with robotic precision, ensuring batch uniformity and reducing contamination risks. This technological evolution enables massive throughput scaling without requiring proportional increases in facility size or staff, as demonstrated by Cellares in September 2024, when it commissioned a New Jersey facility capable of producing up to 40,000 standard CAR-T cell therapy doses annually.

Simultaneously, the rise of decentralized and point-of-care production models is disrupting traditional centralized supply chains by placing manufacturing capabilities within or near clinical environments. This strategy drastically cuts vein-to-vein timelines and logistical hurdles by processing patient material on-site, effectively turning hospitals into biomanufacturing centers. Major academic and clinical institutions are funding this shift, as illustrated by The University of Texas MD Anderson Cancer Center's November 2024 launch of a new institute, backed by over $80 million, to accelerate the internal discovery and manufacturing of cell therapies.

Key Market Players

• Lonza
• Thermo Fisher
• Catalent
• WuXi AppTec
• Novartis
• Gilead
• Bristol Myers Squibb
• Merck KGaA
• Cytiva
• Charles River

Report Scope

In this report, the Global Cell Therapy Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Manufacturing Market, By Therapy

• T-Cell Therapies
• Dendritic Cell Therapies
• Tumor Cell Therapies
• Stem Cell Therapies

Cell Therapy Manufacturing Market, By Source of Cell

• Autologous v/s Allogenic

Cell Therapy Manufacturing Market, By Scale of Operation

• Preclinical
• Clinical
• Commercial

Cell Therapy Manufacturing Market, By Source

• In-House v/s Contract Manufacturing

Cell Therapy Manufacturing Market, By Application

• Oncology
• Cardiovascular Diseases
• Orthopedic Diseases
• Others

Cell Therapy Manufacturing Market, By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Cell Therapy Manufacturing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Manufacturing Market.

Available Customizations:

Global Cell Therapy Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Therapy Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
  • 5.2.2. By Source of Cell (Autologous v/s Allogenic)
  • 5.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
  • 5.2.4. By Source (In-House v/s Contract Manufacturing)
  • 5.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
  • 5.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Cell Therapy Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Source of Cell
  • 6.2.3. By Scale of Operation
  • 6.2.4. By Source
  • 6.2.5. By Application
  • 6.2.6. By End User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Therapy Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Source of Cell
      • 6.3.1.2.3. By Scale of Operation
      • 6.3.1.2.4. By Source
      • 6.3.1.2.5. By Application
      • 6.3.1.2.6. By End User
  • 6.3.2. Canada Cell Therapy Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Source of Cell
      • 6.3.2.2.3. By Scale of Operation
      • 6.3.2.2.4. By Source
      • 6.3.2.2.5. By Application
      • 6.3.2.2.6. By End User
  • 6.3.3. Mexico Cell Therapy Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Source of Cell
      • 6.3.3.2.3. By Scale of Operation
      • 6.3.3.2.4. By Source
      • 6.3.3.2.5. By Application
      • 6.3.3.2.6. By End User

7. Europe Cell Therapy Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Source of Cell
  • 7.2.3. By Scale of Operation
  • 7.2.4. By Source
  • 7.2.5. By Application
  • 7.2.6. By End User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Therapy Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Source of Cell
      • 7.3.1.2.3. By Scale of Operation
      • 7.3.1.2.4. By Source
      • 7.3.1.2.5. By Application
      • 7.3.1.2.6. By End User
  • 7.3.2. France Cell Therapy Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Source of Cell
      • 7.3.2.2.3. By Scale of Operation
      • 7.3.2.2.4. By Source
      • 7.3.2.2.5. By Application
      • 7.3.2.2.6. By End User
  • 7.3.3. United Kingdom Cell Therapy Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Source of Cell
      • 7.3.3.2.3. By Scale of Operation
      • 7.3.3.2.4. By Source
      • 7.3.3.2.5. By Application
      • 7.3.3.2.6. By End User
  • 7.3.4. Italy Cell Therapy Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Source of Cell
      • 7.3.4.2.3. By Scale of Operation
      • 7.3.4.2.4. By Source
      • 7.3.4.2.5. By Application
      • 7.3.4.2.6. By End User
  • 7.3.5. Spain Cell Therapy Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Source of Cell
      • 7.3.5.2.3. By Scale of Operation
      • 7.3.5.2.4. By Source
      • 7.3.5.2.5. By Application
      • 7.3.5.2.6. By End User

8. Asia Pacific Cell Therapy Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Source of Cell
  • 8.2.3. By Scale of Operation
  • 8.2.4. By Source
  • 8.2.5. By Application
  • 8.2.6. By End User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Therapy Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Source of Cell
      • 8.3.1.2.3. By Scale of Operation
      • 8.3.1.2.4. By Source
      • 8.3.1.2.5. By Application
      • 8.3.1.2.6. By End User
  • 8.3.2. India Cell Therapy Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Source of Cell
      • 8.3.2.2.3. By Scale of Operation
      • 8.3.2.2.4. By Source
      • 8.3.2.2.5. By Application
      • 8.3.2.2.6. By End User
  • 8.3.3. Japan Cell Therapy Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Source of Cell
      • 8.3.3.2.3. By Scale of Operation
      • 8.3.3.2.4. By Source
      • 8.3.3.2.5. By Application
      • 8.3.3.2.6. By End User
  • 8.3.4. South Korea Cell Therapy Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Source of Cell
      • 8.3.4.2.3. By Scale of Operation
      • 8.3.4.2.4. By Source
      • 8.3.4.2.5. By Application
      • 8.3.4.2.6. By End User
  • 8.3.5. Australia Cell Therapy Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Source of Cell
      • 8.3.5.2.3. By Scale of Operation
      • 8.3.5.2.4. By Source
      • 8.3.5.2.5. By Application
      • 8.3.5.2.6. By End User

9. Middle East & Africa Cell Therapy Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Source of Cell
  • 9.2.3. By Scale of Operation
  • 9.2.4. By Source
  • 9.2.5. By Application
  • 9.2.6. By End User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Therapy Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Source of Cell
      • 9.3.1.2.3. By Scale of Operation
      • 9.3.1.2.4. By Source
      • 9.3.1.2.5. By Application
      • 9.3.1.2.6. By End User
  • 9.3.2. UAE Cell Therapy Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Source of Cell
      • 9.3.2.2.3. By Scale of Operation
      • 9.3.2.2.4. By Source
      • 9.3.2.2.5. By Application
      • 9.3.2.2.6. By End User
  • 9.3.3. South Africa Cell Therapy Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Source of Cell
      • 9.3.3.2.3. By Scale of Operation
      • 9.3.3.2.4. By Source
      • 9.3.3.2.5. By Application
      • 9.3.3.2.6. By End User

10. South America Cell Therapy Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Source of Cell
  • 10.2.3. By Scale of Operation
  • 10.2.4. By Source
  • 10.2.5. By Application
  • 10.2.6. By End User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Therapy Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Source of Cell
      • 10.3.1.2.3. By Scale of Operation
      • 10.3.1.2.4. By Source
      • 10.3.1.2.5. By Application
      • 10.3.1.2.6. By End User
  • 10.3.2. Colombia Cell Therapy Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Source of Cell
      • 10.3.2.2.3. By Scale of Operation
      • 10.3.2.2.4. By Source
      • 10.3.2.2.5. By Application
      • 10.3.2.2.6. By End User
  • 10.3.3. Argentina Cell Therapy Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Source of Cell
      • 10.3.3.2.3. By Scale of Operation
      • 10.3.3.2.4. By Source
      • 10.3.3.2.5. By Application
      • 10.3.3.2.6. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Therapy Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lonza
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher
• 15.3. Catalent
• 15.4. WuXi AppTec
• 15.5. Novartis
• 15.6. Gilead
• 15.7. Bristol Myers Squibb
• 15.8. Merck KGaA
• 15.9. Cytiva
• 15.10. Charles River

16. Strategic Recommendations

17. About Us & Disclaimer